Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 127,259

Document Document Title
WO/2017/139210A1
In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiadiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable sal...  
WO/2017/138008A3
A method of modulating protein exocytosis is provided. The method comprising contacting a cell with an agent that modulates the ubiquitin pathway in the Golgi, thereby modulating protein secretion.  
WO/2017/139331A1
The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead compositio...  
WO/2017/138008A2
A method of modulating protein exocytosis is provided. The method comprising contacting a cell with an agent that modulates the ubiquitin pathway in the Golgi, thereby modulating protein secretion.  
WO/2017/137469A1
The present invention relates to the field of medicine, specifically the field of treatment and prevention of cardiovascular diseases.  
WO/2017/137600A1
The present invention relates to methods for treating neurodegenerative diseases and disorders with igmesine.  
WO/2017/138838A1
The invention relates to salts and hydrates of arylcycloalkylamine derivatives of general formula (I) and formula (II), where in formula (I), R1 and R2 signify H, a linear or branched alkyl (C1, C4), a linear or branched alkoxy (C1, C4),...  
WO/2017/139603A1
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-t...  
WO/2017/139331A8
The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead compositio...  
WO/2017/136922A1
The present disclosure discloses trehalose for use in treatment of neurological disorders, wherein the trehalose is for a single daily administration with the daily dose between about 0.25 to about 12.5 g/kg/day. The daily dose may be ab...  
WO/2017/139428A1
Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B r...  
WO/2017/138586A1
To provide a novel inflammasome inhibitor capable of inhibiting the activation of inflammasome, the present inventors newly found that arctigenin reduces the release amount of 1L-1β and the amount of activated caspase-1 upon stimulation...  
WO/2017/139487A1
Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and ner...  
WO/2017/137528A1
The present invention is directed to an adenosine A1 receptor agonist for use in treatment of status epilepticus, in particular to theuse of N-cyclohexyl-2'-O-methyladenosine (SDZ WAG 994)in the treatment of status epilepticuswithout pri...  
WO/2017/137988A1
The present invention provides pharmaceutical compositions comprising a metal- desferrioxamine B complex or a combination thereof, for preventing, inhibiting, reducing or ameliorating neurodegeneration, thereby treating diseases, disorde...  
WO/2017/132752A1
A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in...  
WO/2017/135462A1
The purpose of the present invention is to provide a novel compound having TRPA1 antagonist activity, a medicine containing the compound, and a pharmaceutical agent applicable to prophylaxis or treatment of diseases associated with TRPA1...  
WO/2017/133681A1
The present application relates to a compound represented by formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides...  
WO/2017/133517A1
Disclosed are a phosphamide derivative, a method for manufacturing the same, and uses thereof Particularly disclosed are a compound shown by general formula (I) as well as a pharmaceutically acceptable salt or stereisomer (I) thereof, wh...  
WO/2017/134038A1
The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 µm and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for...  
WO/2017/133714A1
An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a ...  
WO/2017/133337A1
The present invention provides a substituted benzimidazolone compound and a composition comprising the same. The present invention discloses a substituted benzimidazolone compound represented by formula (I) and a pharmaceutical compositi...  
WO/2017/136375A1
This invention relates to deuterated forms of morpholinobenzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxa mide compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of ...  
WO/2017/135399A1
A compound having TrkA inhibitory activity, or a pharmaceutically permissible salt thereof are provided. This invention relates to a compound represented by formula (I) or a pharmaceutically permissible salt thereof, and to a pharmaceuti...  
WO/2017/133990A1
The present invention relates to compounds of formula I wherein R1' is CH3; R1 is CH3, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, CH3, ethyl, isopro...  
WO/2017/134280A1
The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death. More specifically, the present invention relates to novel combinatorial therapies ...  
WO/2017/133518A1
An application using an icariin and an icariin derivative, a pharmaceutically acceptable salt thereof, an Epimedium flavonoid comprising the icariin or the icariin derivative, and an Epimedium extract comprising the icariin or the icarii...  
WO/2017/134468A1
The invention relates to a novel salt of cytisine and pharmaceutical compositions comprising that salt. In particular, the invention relates to a succinate salt of cytisine which displays improved excipient compatibility, permitting the ...  
WO/2017/133634A1
The present invention relates to an opioid receptor antagonist conjugate and a use thereof. In particular, the present invention relates to a covalent coupling conjugate of a hydrophilic polymer and an opioid receptor antagonist and the ...  
WO/2017/136376A1
The present invention relates to compositions and methods for the delivery of agents to a subject, particularly to the central nervous system (CNS).  
WO/2017/136834A1
The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently ...  
WO/2017/133258A1
Disclosed in is a 1H-indazole derivative as shown in formula (A), and also disclosed is a method for preparing the compound and the use thereof as an IDO inhibitor. The compound of the present invention can be used for preventing and/or ...  
WO/2017/131097A1
Provided is a pharmaceutical composition for the treatment or prevention of a cognitive disease or disorder, the composition comprising a compound represented by formula (1), an enantiomer thereof or diasteriomer thereof, or a pharmaceut...  
WO/2017/130638A1
Provided is a material effective for improving the activity of nerves in the brain or for preventing or remedying brain dysfunction. Disclosed is an agent for activating astrocyte glucose metabolism comprising, as an active ingredient, a...  
WO/2017/131601A1
The invention relates to a molecule enabling removal of neurotoxicity observed in neuron cells due to various reasons.  
WO/2017/128291A1
Provided is an application of berberine in preparing a pharmaceutical to prevent and/or treat Alzheimer's disease. Berberine can reduce the protein levels of Aβ, APP, phosphorylated tau422, and phosphorylated tau396, and can improve the...  
WO/2017/130190A1
This invention provides a novel formulation for effective delivery of a pharmaceutically active ingredient such as a peptide possessing neuroprotective activity. Also provided are methods for treating pertinent clinical implications such...  
WO/2017/131149A1
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity makes it possible to obtain a therapeutic agent for S1P5-me...  
WO/2017/131156A1
The purpose of the present invention is to provide a novel compound having antagonist activity against retinoid-related orphan receptor γ, and exhibiting a therapeutic effect or a preventive effect for an autoimmune disease such as mult...  
WO/2017/132155A1
The invention provides methods of treating schizophrenia in a subject, including for example, administering to the subject an agent that inhibits expression or activity of a C4A polynucleotide or polypeptide. The invention also provides ...  
WO/2017/129139A1
Provided in the present invention are a sulfamic acid ester as an indoleamine-2,3-dioxygenase inhibitor, a preparation method therefor and a use thereof. The structure of the inhibitor in the present invention is shown in general structu...  
WO/2017/129829A1
The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compound...  
WO/2017/130108A1
The present invention relates to a formulation for use in treating migraine aura comprising, as active ingredients, an extract of Tanacethum parthenium, magnesium cations, 5-hydroxy-tryptophan. The present invention further relates to a ...  
WO/2017/129782A1
The present invention relates to highly soluble, non-fluorescent and photostable myosin inhibitors; especially, for in vivo inhibition of the ATPase activity of neuronal non-muscle myosin 2 of formula (II): wherein Q1, Q2, Q3, Q4, R1, R2...  
WO/2017/130859A1
A neuronal cell death inhibitor having as an active ingredient a bacterium belonging to Bifidobacterium longum, such as Bifidobacterium longum subspecies infantis LMG 23728 or Bifidobacterium longum subspecies longum ATCC 15707, or a cul...  
WO/2017/132432A8
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutica...  
WO/2017/131171A1
Provided is a compound represented by general formula (I) and a pharmaceutically acceptable salt thereof. [In formula (I): A1 is a methylene group, and the like; A2 is a methylene group or an oxygen atom; A3 is an azetidinyl group, pyrro...  
WO/2017/132432A1
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical...  
WO/2017/129061A1
Disclosed is an application of substituted cinnamamide derivatives in the preparation of Anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable sa...  
WO/2017/129987A1
Compositions comprising a nutritionally or pharmaceutically effective dosage of an extract of Salvia officinalis and an acceptable carrier are provided. The compositions show particular potential in the treatment of age-related pathologi...  

Matches 501 - 550 out of 127,259